The efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetes A 52-week randomised, treat-to-target, placebo-controlled, double-blinded, parallelgroup, multinational, multi-centre trial

To confirm the efficacy of liraglutide as adjunct to insulin treatment on glycaemic control, and to confirm the superiority of liraglutide treatment compared to placebo, both adjunct to insulin treatment, with regards to reduction in total daily insulin dose and body weight loss, after 52 weeks of treatment in subjects with established type 1 diabetes with inadequate glycaemic control.